Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

77 more hepatitis cases may trace to clinic, officials say
LAS VEGAS -- Seventy-seven more people that were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said. Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist

77 more hepatitis cases may trace to clinic at center of Las Vegas outbreak, officials say
AM LAS VEGAS-Seventy-seven more people that were treated at a Las Vegas outpatient clinic accused of reusing syringes on thousands of people have been diagnosed with Hepatitis C, health officials said. Authorities cannot say for sure how the 77 people

77 more hepatitis cases may trace to clinic, officials say
Seventy-seven more people that were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said.Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist with the


UPDATES AND COMMENTARY RSS Feed

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...

Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....

Am J Gastroenterol 1997 Dec;92(12):2197-2200

Genetic distinctions between types 1 and 2 autoimmune hepatitis.

Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP

OBJECTIVES:

Our aim was to determine whether alleles affecting susceptibility to type 1 autoimmune hepatitis in the United States occur as commonly in German patients with type 2 disease. METHODS: DNA specimens from 12 German patients with type 2 autoimmune hepatitis were tested for class II alleles of the major histocompatibility complex by polymerase chain reaction using sequence specific primers. Eighty-six American patients with type 1 disease and 102 Caucasoid normal subjects from the United States were tested in a similar manner.

RESULTS:

American patients with type 1 autoimmune hepatitis had DRB1*03 alleles more commonly than the German patients with type 2 disease (51% vs 17%, p = 0.03) and DRB1*0301 occurred more frequently in the type 1 patients (51% vs 17%, p = 0.03). The frequency of DRB1*04 alleles was also higher in the type 1 patients after exclusion of the DR1*03 alleles (64% vs 20%, p = 0.01). In contrast, patients with type 2 disease more commonly had DRB1*07 (p = 0.003), DRB1*15 (p = 0.004), and DQB1*06 (p = 0.0004). DRB1*07 (p = 0.005), DRB4*01 (p = 0.03), and DQB1*06 (p= 0.03) also occurred more frequently in the type 2 patients from Germany than in the normal subjects from the United States, although none of these frequencies were statistically significant by an adjusted p value.

CONCLUSIONS:

German patients with type 2 autoimmune hepatitis do not have the same susceptibility alleles as American patients with type 1 disease. Regional differences in prevalence may reflect the genetic profiles of the populations at risk.

PMID: 9399751, UI: 98060672

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 09 May 2008